FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Dickson Brian 		2. Issuer Name and Ticker or Trading Symbol

CRITICAL THERAPEUTICS INC [ CRTX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O CORNERSTONE THERAPEUTICS INC., 2000 REGENCY PARKWAY, SUITE 255 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/31/2008
(Street)

CARY, NC 27518
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock (Right to Buy)   $0.43   10/31/2008     A     65473         (1) 8/1/2015   Common Stock   65473     (2) 65473   D    
Option to Purchase Common Stock (Right to Buy)   $0.43   10/31/2008     A     35712         (3) 3/16/2017   Common Stock   35712     (4) 101185   D    
Option to Purchase Common Stock (Right to Buy)   $0.43   10/31/2008     A     77377         (5) 5/9/2015   Common Stock   77377     (6) 178562   D    
Option to Purchase Common Stock (Right to Buy)   $1.77   10/31/2008     A     178562         (7) 8/1/2015   Common Stock   178562     (8) 357124   D    
Option to Purchase Common Stock (Right to Buy)   $3.90   10/31/2008     A     23808         (9) 10/31/2018   Common Stock   23808     (10) 380932   D    

Explanation of Responses:
( 1)  The vesting schedule for this option award is 25% on February 9, 2007, 25% on February 9, 2008, 25% on February 9, 2009, and 25% on February 9, 2010.
( 2)  Received in the merger (the "Merger") of Neptune Acquisition Corp., a wholly owned subsidiary of Critical Therapeutics, Inc., into Cornerstone BioPharma Holdings, Inc. ("CBPHI") in exchange for stock options to acquire 275,000 shares of CBPHI common stock for $0.10 per share based on an exchange ratio of 0.2380837.
( 3)  The vesting schedule for this option award is 25% on March 16, 2008, 25% on March 16, 2009, 25% on March 16, 2010, and 25% on March 16, 2011.
( 4)  Received in the Merger in exchange for stock options to acquire 150,000 shares of CBPHI common stock for $0.10 per share based on an exchange ratio of 0.2380837.
( 5)  The vesting schedule for this option award is 25% on December 1, 2005, 25% on December 1, 2006, 25% on December 1, 2007, and 25% on December 1, 2008.
( 6)  Received in the Merger in exchange for stock options to acquire 325,000 shares of CBPHI common stock for $0.10 per share based on an exchange ratio of 0.2380837.
( 7)  The vesting schedule for this option award is 25% on August 1, 2006, 25% on August 1, 2007, 25% on August 1, 2008, and 25% on August 1, 2009.
( 8)  Received in the Merger in exchange for stock options to acquire 750,000 shares of CBPHI common stock for $0.42 per share based on an exchange ratio of 0.2380837.
( 9)  The vesting schedule for this option award is 25% on March 15, 2009, 25% on March 15, 2010, 25% on March 15, 2011, and 25% on March 15, 2012.
( 10)  Received in the Merger in exchange for stock options to acquire 100,000 shares of CBPHI common stock for $0.93 per share based on an exchange ratio of 0.2380837.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dickson Brian
C/O CORNERSTONE THERAPEUTICS INC.
2000 REGENCY PARKWAY, SUITE 255
CARY, NC 27518

Chief Medical Officer

Signatures
/s/ David Price, attorney in fact for Brian Dickson pursuant to a power of attorney 11/3/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Cornerstone Therapeutics Inc. (MM) (NASDAQ:CRTXD)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Cornerstone Therapeutics Inc. (MM) 차트를 더 보려면 여기를 클릭.
Cornerstone Therapeutics Inc. (MM) (NASDAQ:CRTXD)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Cornerstone Therapeutics Inc. (MM) 차트를 더 보려면 여기를 클릭.